Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Inclusion Criteria

• •1. 18 years or older
• •2. Diagnosis of primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF
• •3. Enlarged spleen, measuring 5 cm or greater from the costal margin
• •4. Must have two or more of the following risk factors:
• •1. Over 65 years old
• •2. Have the following symptoms often associated with MF: loss of weight, fever, night sweats
• •3. Have a low red blood cell count (anemia - hemoglobin \< 10 g/dL)
• •4. Have a high white blood cell count (history of white blood cell count \> 25,000/uL)
• •5. Have high circulating blasts (\> or = 1%) as measured by blood tests
• •5. Should have circulating blasts \<10% (as measured by blood tests)
• •6. Should be capable of self-care
• •7. Should have adequate bone marrow reserve
• •8. Should not have the option of stem cell transplantation
• •9. Should discontinue any prior or ongoing treatment for myelofibrosis prior to entering the study
• •10. Had no prior treatment with another JAK inhibitor